VVOS News and Press, Vivos Therapeutics Inc. From 08/09/22

LITTLETON, Colo., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to mod...

Vivos Therapeutics (NASDAQ: VVOS) , a revenue-generating medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, has been cleared to treat obstru...

Australia clears Vivos technology to treat obstructive sleep apnea for all ages and regardless of severity in broad regulatory win. Vivos Therapeutics, Inc . (NASDAQ: VVOS) is pleased to announce that it has received multiple Class I clearances by the Therapeutic Goods...

Vivos Therapeutics ( NASDAQ: VVOS ) on Wednesday said it had entered into a distribution agreement with UK-based GM Instruments for GM's NR6 Rhinomanometer, which offers a quick, non-invasive test to measure the function of the nose during active breathing. GM's NR6 Rhinom...

Trevi Therapeutics ( TRVI ) +36% reports positive results from the Ph2b/3 PRISM trial of Haduvio in the treatment of Prurigo nodularis. Catalyst Biosciences CBIO +26% plans to distribute $65M cash to stockholders. 2U TWOU +18% as Byju's reportedly mak...

Vivos Therapeutics ( NASDAQ: VVOS ) entered into an exclusive distribution agreement with GM Instruments for the distribution of GM Instruments’ NR6 Rhinomanometer, the only FDA approved 4-phase rhinomanometer available in the U.S. used to calculate nasal airw...

LITTLETON, Colo., June 29, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . (NASDAQ: VVOS) (“Vivos” or “the Company”), a revenue-stage medical technology company focused on developing innovative treatments for patients suffering from dentofacial abn...

Gainers: Evoke Pharma EVOK +52%. Zynerba Pharmaceuticals (ZYNE) +18%. LifeMD (LFMD) +13%. Vivos Therapeutics (VVOS) +12%. ACADIA Pharmaceuticals ACAD +11%. Losers: 180 Life Sciences (ATNF) -31%. Belite Bio (BLTE) -19%. VectivBio VECT -14%...

Gainers: Gelesis (GLS) +14%. Entrada Therapeutics (TRDA) +10%. Rhythm Pharmaceuticals (RYTM) +9%.  Vivos Therapeutics (VVOS) +7%. Genfit (GNFT) +6%. Losers: Outset Medical (OM) -31%. Arcellx (ACLX) -17%. Neptune Wellness Solutions NEPT -12%. H...

LITTLETON, Colo., June 14, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . (NASDAQ: VVOS) (“Vivos” or “the Company”), a revenue-generating medical technology company focused on developing innovative treatments for patients suffering from dentofacia...